Skip to main content

Table 3 Unajusted median progression free and overall survival (95% Cl)

From: Retrospective analysis of the impact of platinum dose reduction and chemotherapy delays on the outcomes of stage III ovarian cancer patients

 

N

PFS (months)

OS (months)

No platinum reduction or delays

15

15.4 (9.3 – 21.4)

35.8 (16.1 – 55.6)

Platinum reduction only

11

13.1 (10.7 – 34.5)

28.8 (20.5 – 37.2)

Delays only

12

10.8 (4.2 – 17.4)

15.8 (11.9–19.8)

Both Platinum reduction and delays

44

18.3 (10.9 – 25.7)

39.6 (26.2 – 52.4)